Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study.

Juan I Castiglione, Alberto D Rivero,Fabio Barroso,Patricio Brand,Andrea Lautre,Alejandro A Kohler

Journal of clinical neuromuscular disease（2022）

引用 1|浏览3

暂无评分

摘要

Low-dose RTX infusions were sufficient to achieve undetectable CD19/20 cell counts and sustained clinical remission. In low and middle-income countries, the impact of low-dose RTX therapy represents a paradigm shift in decision-making for long-term treatment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要